Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

The presentation will report data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Session Clinical Trial Updates in Radionuclide Theranostics Investor Contact Charles Y. Huang, MBA Director of Capital Markets and Investor Relations Office: (202)-209-5751 | Direct (301)-728-7222 chuang@plustherapeutics.com Title Targeted Radiolabeled Nanoliposo ...